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Abstract
Introduction Ductal carcinoma in situ (DCIS) is characterised
by the intraductal proliferation of malignant epithelial cells.
Several histological classification systems have been
developed, but assessing the histological type/grade of DCIS
lesions is still challenging, making treatment decisions based on
these features difficult. To obtain insight in the molecular basis
of the development of different types of DCIS and its
progression to invasive breast cancer, we have studied
differences in gene expression between different types of DCIS
and between DCIS and invasive breast carcinomas.
Methods Gene expression profiling using microarray analysis
has been performed on 40 in situ and 40 invasive breast cancer
cases.
Results DCIS cases were classified as well- (n  = 6),
intermediately (n = 18), and poorly (n = 14) differentiated type.
Of the 40 invasive breast cancer samples, five samples were
grade I, 11 samples were grade II, and 24 samples were grade
III. Using two-dimensional hierarchical clustering, the basal-like
type, ERB-B2 type, and the luminal-type tumours originally
described for invasive breast cancer could also be identified in
DCIS.
Conclusion Using supervised classification, we identified a
gene expression classifier of 35 genes, which differed between
DCIS and invasive breast cancer; a classifier of 43 genes could
be identified separating between well- and poorly differentiated
DCIS samples.
Introduction
Ductal carcinoma in situ (DCIS) of the breast represents a het-
erogeneous group of non-invasive breast tumours commonly
detected in women undergoing screening mammography.
DCIS is characterised by malignant epithelial cells accumulat-
ing in the ducts of the breast without invading through the
basement membrane into the surrounding tissue. DCIS
accounts for approximately 3% of symptomatic breast malig-
nancies and for approximately 20% of breast malignancies in
patients from population-based screening programs [1].
Different histological types of DCIS can be recognised, and a
variety of classification systems have been developed [2]. Due
to subjective interpretation of the morphology of the lesions,
even experienced pathologists differ in their classification of
DCIS [3]. Therefore, histological classification of DCIS may
not be sufficient, and additional classification approaches
could assist pathological classification.
It is assumed that most cases of DCIS will progress to invasive
breast cancer. Because this progression may take many years
and may not occur within the lifetime of a patient, elucidating
the mechanisms of progression from in situ lesions to invasive
disease and developing diagnostic tests would be of great
clinical benefit.
Several models of the evolution of DCIS to invasive cancer
have been suggested. One model suggests the linear progres-
sion from low-nuclear-grade DCIS to high-nuclear DCIS and
DCIS = ductal carcinoma in situ; ER = oestrogen receptor; IDC = invasive ductal carcinoma; IHC = immunohistochemistry; LCIS = lobular carcinoma 
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the subsequent development of invasive cancer [4]. Based on
specific genetic alterations found in the different types of
DCIS, a more likely scenario is the evolution of well-, moder-
ately, and poorly differentiated DCIS via distinct pathways. Fol-
lowing this idea, well-differentiated DCIS can give rise to low-
grade invasive carcinoma, whereas poorly differentiated DCIS
can give rise to high-grade invasive breast cancer [5,6].
Several specific genetic alterations have been found in DCIS.
HER2 gene amplification and protein overexpression are
detected in up to 70% of poorly differentiated DCIS cases [7],
and cyclin D1 is amplified and overexpressed in DCIS [8] in
approximately 20% of the cases. Inactivating mutations of the
E-cadherin gene are detected in almost all cases of lobular
carcinoma in situ (LCIS) [9]. Several other genetic alterations
in oncogenes (for example, C-MYC) and tumour suppressor
genes (for example, p53) have been found in DCIS and are
reviewed in Reis-Filho and colleagues [10] and Allred and col-
leagues [11].
Gene expression profiling has been shown to be a powerful
tool for identifying profiles of tumour subtypes [12-15] and for
correlating gene expression profiles with outcome in breast
cancer [16-18]. The identification of specific gene expression
patterns correlated with the different types of DCIS may help
to elucidate the processes underlying the evolution of in situ
carcinomas of the breast and also lead to a more reproducible
classification of DCIS lesions.
To date, only a few studies of gene expression profiling of
DCIS and a comparison with the gene expression pattern of
invasive samples have been published and these are based on
a small number of samples [19,20].
In the study presented here, gene expression profiling was
performed on one LCIS and 39 DCIS samples to identify dif-
ferentially expressed genes between well-, intermediately, and
poorly differentiated DCIS. In addition, differences in gene
expression between these cases of carcinoma in situ and 40
invasive breast carcinomas were studied.
Materials and methods
Selection of samples
Cases of DCIS were selected from the tissue bank of the
Netherlands Cancer Institute (Amsterdam, The Netherlands).
These samples were obtained within 1 hour after surgery from
patients who underwent wide local excision (n = 16) or mas-
tectomy (n = 24). All samples were reviewed by two patholo-
gists independently to determine the histological classification
of the samples according to Holland and colleagues [21];
samples were classified as well, intermediately, or poorly dif-
ferentiated. For analysis purposes, the intermediately differen-
tiated DCIS cases were subclassified as those cases that
were in part well differentiated (well to intermediately differen-
tiated) and those that were in part poorly differentiated (mod-
erately to poorly differentiated) in some areas. In cases in
which there was a discrepancy in classification between the
two pathologists, the histological slides were reviewed
together to reach an agreement.
In addition, 40 cases of primary invasive breast cancer were
selected; these were all cases of invasive ductal carcinoma
(IDC) measuring between 1 and 5 cm and were graded as
grade 1, 2, or 3 according to the method described by Elston
and Ellis [22]. The study was approved by the medical ethical
committee of the Netherlands Cancer Institute.
RNA isolation and amplification
RNA isolation and amplification were performed essentially as
described by Weigelt and colleagues [23]. Thirty tissue sec-
tions of 30 μm of frozen material were cut. The first and the last
tissue sections were 6 μm in thickness and were stained with
haematoxylin and eosin to determine the percentage of tumour
cells and to exclude invasive growth. Only samples with
greater than or equal to50% of tumour cells were used for
gene expression profiling.
Immunohistochemistry
The procedures applied are described in the supplementary
information provided online [24].
Microarray hybridisation
Labeling of the amplified cRNA and microarray hybridisations
were performed as previously described [25]. Equal amounts
of amplified cRNAs of 100 invasive breast carcinomas were
pooled and used as a reference. All hybridisations were per-
formed on 18K human cDNA arrays (Central Microarray Facil-
ity, Netherlands Cancer Institute) [26].
Microarrays were scanned with the DNA Microarray Scanner
G2565B (Agilent Technologies, Santa Clara, CA, USA). Self-
self hybridisations were used to validate the quality of the
hybridisations and as a negative control in the error model.
Processing of microarray data
Information on data processing is provided in the supplemen-
tary information [24].
Unsupervised hierarchical clustering
Two-dimensional unsupervised hierarchical clustering using
Pearson correlation as distance function and complete linkage
was performed using Genesis software (Technical University,
Graz, Austria) [27,28].
Supervised classification
We performed supervised classification applying methods
described previously [16,29,30]. Pathological features (histo-
logical type of the DCIS samples, histological grade of the
invasive samples) were used to define groups for supervised
classification. Genes were rank-ordered based on their signal-Available online http://breast-cancer-research.com/content/8/5/R61
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to-noise statistic. Safe cutoffs were determined by comparing
the signal-to-noise ratio (SNR) values with the results from
2,000 sample label permutations (Monte Carlo randomisa-
tion). For each group and a number of genes, a centroid is
defined as the mean ratio per gene over all samples in that
group. Correlation or Euclidean distance of each sample to
those centroids determines their predicted group. Leave-out
cross-validation was used to determine the optimal number of
genes separating the groups. The number of left-out samples
in this cross-validation procedure was dependent on the
number of samples within the analysis set. SNR calculation,
Monte Carlo randomisation, and cross-validation have been
described previously [25].
Supplementary information
The microarray data, additional information on the methods,
and the filtering results are provided as supplementary infor-
mation [24].
Results
This study was performed to identify differences in gene
expression (a) between DCIS and invasive breast cancer and
(b) between different histological types of DCIS.
Tumour characteristics
Thirty-nine cases of DCIS of the breast were included in the
analyses. By histological examination, they were assigned to
the following groups: well differentiated (n = 6), intermediately
differentiated (n = 18), and poorly differentiated (n = 14). For
analysis purposes, the group of intermediately differentiated
cases was further subdivided in well-intermediately (n = 10),
true intermediately (n = 2), and intermediately-poorly (n = 6)
differentiated type. One sample contains a mixture of well- and
poorly differentiated DCIS components in the same tissue
specimen. In addition, one case of LCIS was included.
To be able to compare DCIS with invasive breast cancer, 40
cases of invasive breast cancer were studied. Five tumours
were histological grade 1, 11 samples were grade 2, and 24
samples were grade 3. Patient and tumour characteristics are
summarised in Table 1.
Molecular subtypes of breast cancer
Several subtypes of breast cancer have been identified by
gene expression profiling and have been correlated with clini-
cal outcome [13,14]. This classification has been translated to
classical immunohistochemistry (IHC): basal-type tumours are
characterised by negative staining for oestrogen receptor
(ER), progesterone receptor, and HER2 and are often positive
for keratin 5/6; ERB-B2 tumours are HER2-positive, and lumi-
nal A and B tumours are ER-positive and HER2-negative. In
our set of 40 in situ tumours, only two tumours are positive for
CK5/6 by IHC. Both of them are poorly differentiated and neg-
ative for HER2 and ER by IHC. From the intrinsic gene set
identified by Perou and colleagues [12], we could match 403
identifiers to our array platform. This set of genes was used to
perform unsupervised hierarchical clustering of the 40 in situ
samples. We clearly see a discrimination between tumours
highly expressing genes of the luminal/ESR1 cluster and
tumours negative for these genes, whereas the discrimination
for the HER2-overexpressing groups was much less clear
(Figure 1 in the supplementary information [24]). We could not
identify a large basal-type group, which is in agreement with
the data obtained using IHC.
Unsupervised hierarchical clustering
Unsupervised hierarchical clustering of in situ and invasive 
samples
First, the whole group of DCIS and invasive samples was clus-
tered (Figure 1a). As can be seen, the invasive samples cluster
in three different groups (indicated as I, II, and III in Figure 1a).
Ten out of 14 poorly differentiated DCIS samples cluster
together in a fourth group, and a fifth group consists of 13 out
of 18 cases of intermediately differentiated DCIS and four out
of six of the well-differentiated in situ samples. The clustering
seems not to be driven mainly by the ER status or the HER2
status of the samples. These results suggest that poorly differ-
entiated DCIS samples show an overall gene expression pro-
file other than that of the intermediately and well-differentiated
DCIS samples.
Unsupervised hierarchical clustering of DCIS
We also performed unsupervised hierarchical cluster analysis
to the series of DCIS cases only, resulting in two large groups.
One group contains 10 poorly differentiated samples and only
one well-differentiated sample, whereas 83% of the well-differ-
entiated samples group in the other, second cluster. Most of
the samples in this second group are ER-positive by IHC. In
total, our sample set contains 18 cases with an intermediately
differentiated component. Of these samples, 12 cluster in the
arm of the well-differentiated samples. In accordance with the
clustering results presented in Figure 1, these results also indi-
cate that the overall gene expression profiles of in situ samples
with an intermediately differentiated component are more sim-
ilar to those of well-differentiated DCIS than to those of poorly
differentiated DCIS. It is clear from these results that there are
large differences in gene expression pattern between well-
and poorly differentiated DCIS.
Supervised classification
We performed supervised classification on different data sets
to identify the genes differentially expressed between the
groups of interest. These groups are (a) 40 in situ versus 40
invasive breast carcinomas, (b) 14 poorly differentiated DCIS
cases versus 38 invasive grade 3 tumours, and (c) six cases of
well-versus 14 cases of poorly differentiated DCIS.Breast Cancer Research    Vol 8 No 5    Hannemann et al.
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Supervised classification of in situ versus invasive 
carcinomas
We investigated the differences in gene expression between
in situ and invasive breast carcinoma samples. We therefore
used the whole data set and assigned all 40 in situ samples to
one group and all 40 invasive samples to a second group
(analysis set 1). To obtain a profile taking into account the
expression sets of both tumour types, significantly regulated
genes were identified independently for both groups. The
1,706 overlapping genes were used for analysis. Monte Carlo
randomisation revealed approximately 300 genes differentially
expressed between in situ and invasive samples.
After cross-validation, classifier consisting of 35 genes
resulted in a stable prediction of the differences between
DCIS and invasive breast carcinomas, with an average per-
formance of 91%. The gene list is provided in Table 2.
Supervised classification for poorly differentiated DCIS 
versus grade 3 invasive carcinoma
Because it is very likely that grade 3 invasive breast cancer
arises from poorly differentiated DCIS [5,6], we applied the
supervised classification procedure to the subset of poorly dif-
ferentiated DCIS (n = 14) and grade 3 invasive tumours (n =
24) (analysis set 2). Again, the filtering procedure was applied
to both groups independently. The overlapping fraction of this
gene list contains 1,119 genes that were used to perform the
analyses. Monte Carlo randomisation showed that 80 genes
are differentially expressed between poorly differentiated
DCIS and grade 3 invasive breast carcinoma samples. After
cross-validation in 14 steps, the best performance of 93% is
reached, when at least 50 genes are used to build the classi-
fier. This performance remains stable with increasing numbers
of genes. This means that 50 to 80 genes are able to discrim-
inate between poorly differentiated DCIS and invasive grade 3
Table 1
Patient characteristics
In situ samples Invasive samples
Differentiation Number (percentage) Histological grade Number (percentage)
Well 6 (15%) 1 5 (12.5%)
Intermediately 18 (45%) 2 11 (27.5%)
Poorly 14 (35%) 3 24 (60%)
Good/poor component 1 (2.5%)
LCIS 1 (2.5%)
IHC IHC
ER-positive 28 (70%)a ER-positive 22 (55%)c
PR-positive 24 (60%)a PR-positive 19 (47.5%)d
Her2/neu-positive (3+) 12 (30%)b Her2/neu-positive (3+) 4 (10%)d
p53-positive 11 (27.5%)b p53-positive 9 (22.5%)d
Tumour detection
Palpation 17 (42.5%)
Microcalcifications 18 (45%)
Others 5 (12.5%)
Tumour diameter (mm)
Range 10 to 80
Median 45
Average 42.8
Treatment
Mastectomy 24 (60%)
Breast conserving treatment 6 (15%)
Local excision followed by 
mastectomy
10 (25%)
a5% not assessable, b2.5% not assessable, c27.5% not assessable, d30% not assessable. ER, oestrogen receptor; IHC, immunohistochemistry; 
LCIS, lobular carcinoma in situ; PR, progesterone receptor.Available online http://breast-cancer-research.com/content/8/5/R61
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breast tumours (Figure 2a). These 80 genes are shown in
Table 3. Between the 35-gene classifier of all DCIS and inva-
sive samples and the subgroup classifier of 80 genes, 21
genes were present in both classifiers.
Supervised classification of well-versus poorly differentiated 
DCIS
We intended to find the most prominent differences between
the well- and poorly differentiated DCIS samples. Sixfold
cross-validation of six well- and 14 poorly differentiated in situ
samples (analysis set 3) resulted in a set of 43 genes separat-
ing these groups with a performance of 90% (Figure 3a, Table
4).
Because histological classification of intermediately differenti-
ated DCIS versus well- or moderately differentiated DCIS is
most challenging, we investigated whether gene expression
profiling could be used to identify markers that could help in
Figure 1
Unsupervised hierarchical clustering of in situ and invasive samples Unsupervised hierarchical clustering of in situ and invasive samples. (a) Dendrogram of all in situ (n = 40) and all invasive (n = 40) samples. (b) 
Scaled-down representation of the entire cluster shown in (a) (1,706 genes). (c) Dendogram of poorly differentiated ductal carcinoma in situ (n = 
14) and grade 3 invasive (n = 24) samples. (d) Entire cluster of (c) (1,119 genes). Yellow indicates in situ samples, and blue indicates invasive sam-
ples. i, intermediately differentiated; IHC, immunohistochemistry; i/p, intermediately/poorly differentiated; LCIS, lobular carcinoma in situ; p, poorly 
differentiated; w, well differentiated; w/i, well/intermediately differentiated.Breast Cancer Research    Vol 8 No 5    Hannemann et al.
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making this classification. We therefore included the cases
classified as intermediately differentiated DCIS. Subse-
quently, we divided the sample set into one group of well/well-
intermediately differentiated samples (n = 16) and a second
group containing poorly/intermediately-poorly differentiated
samples (n  = 20). Supervised classification of these data
revealed a set of 78 genes separating these two groups with
an average performance of 89% (Table 5).
Table 2
List of 35 genes able to discriminate between all DCIS and all invasive samples
Rank NKI ID Symbol Annotation Accession no.
1 116810 ADM Adrenomedullin AA446120
2 123346 EST H17315
3 117289 MMP11 Matrix metalloproteinase 11 (stromelysin 3) AA045500
4 121066 DAPK3 Death-associated protein kinase 3 AA973730
5 123776 PIAS4 Protein inhibitor of activated STAT protein H30547
6 101837 DHX34 KIAA0134 gene product AA477623
7 102847 YIF1 Putative transmembrane protein; homolog of yeast Golgi membrane protein Yif1p (Yip1p-interacting factor) H79351
8 117345 ACTN1 Actinin, alpha 1 AA669042
9 127755 TGFB2 Transforming growth factor, beta 2 W47556
10 108960 GABRD Gamma-aminobutyric acid (GABA) A receptor, delta H41122
11 108348 MFAP2 Microfibrillar-associated protein 2 N67487
12 129658 MGC13045 DnaJ (Hsp40) homolog, subfamily C, member 4 AA996059
13 105479 BAT3 HLA-B-associated transcript-3 AA434416
14 120649 KCTD5 Hypothetical protein AA521027
15 110728 FBXL15 F-box and leucine-rich repeat protein 15 T61547
16 120934 EIF4G1 Eukaryotic translation initiation factor 4 gamma, 1 R37276
17 118584 C9orf115 ESTs, weakly similar to B36298 proline-rich protein PRB3S [Homo sapiens] AA479713
18 105533 ARF1 ADP-ribosylation factor 1 W45572
19 131909 TUBB2 Tubulin, beta polypeptide AI672565
20 131540 PRPF31 DKFZP566J153 protein AI253017
21 110281 HSPA1L Heat shock 70-kD protein-like 1 H17513
22 107215 KCTD5 Hypothetical protein AA429470
23 121937 FLJ10374 Hypothetical protein FLJ10374 AA676962
24 100368 GNB2 Guanine nucleotide binding protein (G protein), beta polypeptide 2 N68166
25 105453 PSAP Prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) N72215
26 115391 LMCD1 LIM and cysteine-rich domains 1 AA452125
27 128198 MMP11 Matrix metalloproteinase 11 (stromelysin 3) AA954935
28 123688 COL1A1 Collagen, type I, alpha 1 R48844
29 127890 PTMS Parathymosin AA458981
30 102044 DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) AA406285
31 101067 MAP7 Microtubule-associated protein 7 R77252 | R77251
32 129438 IQGAP1 IQ motif containing GTPase activating protein 1 AA478633
33 125700 APC2 Adenomatous polyposis coli like AA976241
34 127881 NFIC Nuclear factor I/C (CCAAT-binding transcription factor) T59427
35 109065 SYT5 Synaptotagmin V H39018
DCIS, ductal carcinoma in situ; EST, expressed sequence tag; NKI ID, Netherlands Cancer Institute (Amsterdam, The Netherlands) identification 
number.Available online http://breast-cancer-research.com/content/8/5/R61
Page 7 of 20
(page number not for citation purposes)
We observed a separation of this data set in three distinct
groups (Figure 3). One group contains one intermediately-
poorly differentiated sample (17%) and 12 out of 14 poorly dif-
ferentiated samples, and a second group all six well-differenti-
ated samples and seven out of 10 well-intermediately
differentiated samples. The third group shows no correlation
with both profiles and consists of five out of six intermediately-
poorly and three out of 10 well-intermediately differentiated
samples. This implies that this third group typifies mainly the
intermediately-poorly differentiated samples. Well-intermedi-
ately differentiated samples are apparently very similar to well-
differentiated DCIS in their gene expression. These results are
in accordance with the results of unsupervised hierarchical
clustering of all in situ samples (Figure 4a).
Twenty-one genes are overlapping between the 43 genes of
analysis set 3 and the 78 genes of analysis set 4. It is known
that many poorly differentiated in situ breast carcinomas do
not express the ER. In our data set, nine of all 14 poorly differ-
entiated DCIS samples (64%) are negative for ER expression
by IHC. There was a slight chance that our classifier would
detect mainly the differences of ER-associated genes. We
identified only one gene (LIV-1), beside the ER itself, directly
ER-regulated in the classifier of 43 genes. Additionally, we
compared the 43 genes with 2,460 ER-associated genes
identified by van 't Veer and colleagues [16]. Thirteen genes,
including the ER itself, have been found in both gene lists. So,
most of the genes in this 43-gene classifier have not been cor-
related to ER expression so far, indicating that the differences
between well- and poorly differentiated DCIS samples are not
originating from the ER status of the samples.
Remarkably, completely different gene lists are found describ-
ing the differences in gene expression between different in
Figure 2
Euclidean distance and heatmaps of the in situ and invasive samples using the classifiers obtained after cross-validation Euclidean distance and heatmaps of the in situ and invasive samples using the classifiers obtained after cross-validation. (a) All ductal carcinoma in 
situ (DCIS) (n = 40) and all invasive (n = 40) samples. The classifiers consist of 80 genes. (b) Poorly differentiated DCIS (n = 14) versus invasive 
grade 3 samples (n = 24) using a classifier of 35 genes. p, poorly differentiated.Breast Cancer Research    Vol 8 No 5    Hannemann et al.
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Table 3
List of 80 genes able to discriminate between poorly differentiated DCIS and invasive grade 3 breast tumours
Rank NKI ID Symbol Annotation Accession no.
1 123776 PIAS4 Protein inhibitor of activated STAT protein H30547
2 129658 MGC13045 DnaJ (Hsp40) homolog, subfamily C, member 4 AA996059
3 121937 FLJ10374 Hypothetical protein FLJ10374 AA676962
4 102847 YIF1 Putative transmembrane protein; homolog of yeast Golgi membrane protein Yif1p (Yip1p-interacting 
factor)
H79351
5 127755 TGFB2 Transforming growth factor, beta 2 W47556
6 117289 MMP11 Matrix metalloproteinase 11 (stromelysin 3) AA045500
7 104973 SYNPO2 Synaptopodin 2 R31679
8 121066 DAPK3 Death-associated protein kinase 3 AA973730
9 128493 GMFG Glia maturation factor, gamma AI311932
10 105533 ARF1 ADP-ribosylation factor 1 W45572
11 132031 NY-REN-24 antigen AA918005
12 127881 NFIC Nuclear factor I/C (CCAAT-binding transcription factor) T59427
13 120649 KCTD5 Potassium channel tetramerisation domain containing 5 AA521027
14 120934 EIF4G1 Eukaryotic translation initiation factor 4 gamma, 1 R37276
15 105453 PSAP Prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) N72215
16 112695 SYNPO2 H. sapiens cDNA FLJ20767 fis, clone COL06986 AA043349
17 101577 BMI1 Murine leukaemia viral (bmi-1) oncogene homolog AA478036
18 105479 BAT3 HLA-B-associated transcript-3 AA434416
19 123071 C9orf82 Hypothetical protein FLJ13657 AA135972
20 101638 ID4 Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein AA464856
21 115306 LRP16 LRP16 protein AA456318
22 118143 STX1B2 ESTs, moderately similar to ST1B_HUMAN SYNTAXIN 1B [H. sapiens] H41572
23 128106 DUSP6 Dual specificity phosphatase 6 AA455254
24 115676 RPS15A Ribosomal protein S15a AA411682
25 108595 CCL19 Small inducible cytokine subfamily A (Cys-Cys), member 19 AA680186
26 126589 C6orf166 Hypothetical protein FLJ10342 AA984953
27 131540 PRPF31 DKFZP566J153 protein AI253017
28 109065 SYT5 H39018
29 128198 MMP11 Matrix metalloproteinase 11 (stromelysin 3) AA954935
30 109364 MYST2 Histone acetyltransferase H11938
31 106989 TNFSF13 Tumour necrosis factor (ligand) superfamily, member 13 AA443577
32 109798 T82459
33 131890 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) AI671174
34 111513 COG3 H. sapiens clone 25226 mRNA sequence AA461166
35 108645 HMGCS2 3-Hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) AA496149
36 101651 TRAP1 Heat shock protein 75 AA497020
37 105304 LRP16 LRP16 protein W52182 | AA284285
38 105363 ARL7 ADP-ribosylation factor-like 7 AA485683
39 127890 PTMS Parathymosin AA458981
40 118682 NBS1 Nijmegen breakage syndrome 1 (nibrin) H98655Available online http://breast-cancer-research.com/content/8/5/R61
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41 108997 PTTG1IP Pituitary tumour-transforming 1 interacting protein AA156461
42 110281 HSPA1L Heat shock 70-kD protein-like 1 H17513
43 125700 APC2 Adenomatous polyposis coli like AA976241
44 117139 ALDOB Aldolase B, fructose-bisphosphate H72098
45 107595 SOX17 SRY-box 17 AA427400 | AI732705
46 107375 NUCKS Similar to rat nuclear ubiquitous casein kinase 2 AA137266
47 109238 BSG Basigin (OK blood group) AA436440
48 122821 NSE2 ESTs H30453
49 123689 LOC339123 STIP1 homology and U-Box containing protein 1 R54844
50 115953 LOC146542 Human Chromosome 16 BAC clone CIT987SK-A-635H12 AA455010
51 108960 GABRD H41122
52 128222 GLUL Glutamate-ammonia ligase (glutamine synthase) AI000103
53 100222 NFIX Nuclear factor I/X (CCAAT-binding transcription factor) AA406269
54 105470 ISYNA1 Myo-inositol 1-phosphate synthase A1 AA454554
55 117998 RBM9 RNA binding motif protein 9 H03903
56 105404 GDF15 Prostate differentiation factor N26311
57 127811 TOB1 Transducer of ERBB2, 1 W96163
58 105524 RPS6KA4 Ribosomal protein S6 kinase, 90-kD, polypeptide 4 AA443601
59 109232 BCKDHA Branched chain keto acid dehydrogenase E1, alpha polypeptide (maple syrup urine disease) AA477298
60 115741 APPL Adaptor protein containing pH domain, PTB domain and leucine zipper motif AA436158
61 100898 ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific) AA434373
62 101067 MAP7 Microtubule-associated protein 7 R77252 | R77251
63 109306 AQP1 Aquaporin 1 (channel-forming integral protein, 28 kD) H24316
64 102326 CYC1 Cytochrome c-1 AA447774
65 108988 MALAT1 Histone deacetylase 3 H88540
66 102253 ACTG2 Actin, gamma 2, smooth muscle, enteric T60048
67 116834 GPC1 Glypican 1 AA455896
68 105497 HNRPK Heterogeneous nuclear ribonucleoprotein K W85697
69 108372 LCP1 Lymphocyte cytosolic protein 1 (L-plastin) W73144
70 128634 PRCP Prolylcarboxypeptidase (angiotensinase C) AI360366
71 106297 PHF17 Hypothetical protein FLJ22479 AA136664
72 101616 KRT19 Keratin 19 AA464250
73 128532 LTB Lymphotoxin beta (TNF superfamily, member 3) AI351740
74 102385 F13A1 Coagulation factor XIII, A1 polypeptide AA449742
75 102673 WHSC1L1 Wolf-Hirschhorn syndrome candidate 1-like 1 T97900
76 109638 CXXC1 CpG binding protein T60082
77 109116 FBL Fibrillarin AA663986
78 109425 TUBB Tubulin, beta polypeptide AA427899
79 117500 EST AA621138
80 100656 UBE2C Ubiquitin carrier protein E2-C AA430504
DCIS, ductal carcinoma in situ; EST, expressed sequence tag; NKI ID, Netherlands Cancer Institute (Amsterdam, The Netherlands) identification 
number.
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situ samples, on one hand, and DCIS and invasive samples on
the other hand. These findings may indicate that gene regula-
tion involved in progression from in situ to invasive breast can-
cer affects molecular mechanisms other than the mechanisms
responsible for the development of the different types of DCIS.
Discussion
Although studies to identify gene expression signatures in
DCIS are limited by difficulties in obtaining frozen material from
DCIS, we were able to collect a relatively large series of DCIS
cases for this purpose. It should be kept in mind that we did
Figure 3
Correlation plots and heatmaps of the in situ samples using the classifiers obtained after cross-validation Correlation plots and heatmaps of the in situ samples using the classifiers obtained after cross-validation. (a) Well- (n = 6) versus poorly (n = 14) 
differentiated ductal carcinoma in situ (DCIS). The classifiers consist of 43 genes. (b) Well-/well-intermediately (n = 16) versus intermediately-
poorly/poorly (n = 20) differentiated DCIS using a classifier of 78 genes. i-p, intermediately-poorly differentiated; p, poorly differentiated; w, well dif-
ferentiated; w-i, well-intermediately differentiated.Available online http://breast-cancer-research.com/content/8/5/R61
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Table 4
List of 43 genes able to discriminate between well- and poorly differentiated DCIS
Rank NKI ID Symbol Annotation Accession no.
1 108691 ACK1 Activated p21cdc42Hs kinase AA427891
2 109246 BCL2 B-cell CLL/lymphoma 2 W63749
3 109268 ALDH3A2 Aldehyde dehydrogenase 3 family, member A2 AA633569
4 109236 BTD Biotinidase R17765
5 108595 CCL19 Small inducible cytokine subfamily A (Cys-Cys), member 19 AA680186
6 100524 CELSR2 Cadherin, EGF LAG seven-pass G-type receptor 2, flamingo (Drosophila) homolog H39187
7 126868 TMC4 DKFZP586J0619 protein AA991211
8 100708 SLC39A6 LIV-1 protein, oestrogen regulated H29315
9 109170 C4A Complement component 4A AA664406
10 109127 ESR1 Oestrogen receptor 1 AA291749
11 128702 EST AI313031
12 121012 HSHIN1 Hin-1 AA902831
13 128095 PCSK6 Paired basic amino acid cleaving system 4 W85807
14 128052 ARHGEF7 PAK-interacting exchange factor beta AA452871
15 128493 GMFG Glia maturation factor, gamma AI311932
16 123382 HIG1 Likely ortholog of mouse hypoxia induced gene 1 T74105
17 129689 C1orf21 Chromosome 1 open reading frame 21 AA406569
18 102289 ETFA Electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II) T57919
19 126124 FLJ20152 Hypothetical protein AA918685
20 127815 PLAT Plasminogen activator, tissue R38933
21 101559 NPY1R Neuropeptide Y receptor Y1 R43817
22 100260 MAL Mal, T-cell differentiation protein AA227885Breast Cancer Research    Vol 8 No 5    Hannemann et al.
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23 127969 CRYAA Crystallin, alpha A H84722
24 128244 SERPINA3 Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 AA704242
25 108649 Human clone 23948 mRNA sequence H15114
26 106399 GRTP1 Hypothetical protein FLJ22474 N52651
27 123478 FLJ14712 Hypothetical protein FLJ14712 N79050
28 117207 EMP3 Epithelial membrane protein 3 W73810
29 111787 ZNF451 H. sapiens cDNA FLJ13010 fis, clone NT2RP3000542 AA486412
30 109502 KITLG H. sapiens cDNA: FLJ21592 fis, clone COL07036 H11088
31 109315 UCP2 Uncoupling protein 2 (mitochondrial, proton carrier) H61243
32 118532 NUPL1 PRO2463 protein AA772502
33 100263 MYB V-myb avian myeloblastosis viral oncogene homolog N49284
34 128249 CD3E CD3E antigen, epsilon polypeptide (TiT3 complex) AA933862
35 131226 IL7R Interleukin 7 receptor T65739
36 100104 SELL Selectin L (lymphocyte adhesion molecule 1) H00662
37 108671 BCAT2 Branched chain aminotransferase 2, mitochondrial AA436410
38 116984 ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide AA708298
39 108376 LAMA3 Laminin, alpha 3 (nicein [150 kD], kalinin [165 kD], BM600 [150 kD], epilegrin) AA001432
40 104944 SLC7A2 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 R26163
41 100840 THOC1 Nuclear matrix protein p84 AA129297
42 100650 SHFM1 Deleted in split-hand/split-foot 1 region H85464
43 101429 SIAT1 Sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase) AA598652
DCIS, ductal carcinoma in situ; EST, expressed sequence tag; NKI ID, Netherlands Cancer Institute (Amsterdam, The Netherlands) identification 
number.
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Table 5
List of 78 genes able to discriminate between well/well-intermediately and intermediately-poorly/poorly differentiated DCIS
Rank NKI ID Symbol Annotation Accession no.
1 111275 EST H20757
2 109268 ALDH3A2 Aldehyde dehydrogenase 3 family, member A2 AA633569
3 109236 BTD Biotinidase R17765
4 110384 KPNA2 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) AA676460
5 131448 PLEKHG1 KIAA1209 protein AI301815
6 108691 ACK1 Activated p21cdc42Hs kinase AA427891
7 107840 EPC1 ESTs AA120875
8 126868 TMC4 DKFZP586J0619 protein AA991211
9 106257 FLJ32499 H. sapiens cDNA FLJ12749 fis, clone NT2RP2001149 W56590
10 128493 GMFG Glia maturation factor, gamma AI311932
11 128702 AI313031
12 129547 METAP2 Methionine aminopeptidase; eIF-2-associated p67 AA283030
13 111787 ZNF451 H. sapiens cDNA FLJ13010 fis, clone NT2RP3000542 AA486412
14 103209 RBMS1 H. sapiens mRNA; cDNA DKFZp564H0764 (from clone DKFZp564H0764) R62566
15 108595 CCL19 Small inducible cytokine subfamily A (Cys-Cys), member 19 AA680186
16 129267 AA609203
17 109127 ESR1 Oestrogen receptor 1 AA291749
18 100263 MYB V-myb avian myeloblastosis viral oncogene homolog N49284
19 100524 CELSR2 Cadherin, EGF LAG seven-pass G-type receptor 2, flamingo (Drosophila) homolog H39187
20 100260 MAL Mal, T-cell differentiation protein AA227885
21 102995 PIGT CGI-06 protein H82992
22 108649 Human clone 23948 mRNA sequence H15114
23 109246 BCL2 B-cell CLL/lymphoma 2 W63749
24 100203 TNFAIP3 Tumour necrosis factor, alpha-induced protein 3 AA476272
25 107809 XBP1 X-box binding protein 1 W90128
26 102921 H. sapiens mRNA; cDNA DKFZp434D0818 (from clone DKFZp434D0818) N95578Breast Cancer Research    Vol 8 No 5    Hannemann et al.
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27 108671 BCAT2 Branched chain aminotransferase 2, mitochondrial AA436410
28 101925 EZH2 AA430744
29 123382 HIG1 Likely ortholog of mouse hypoxia induced gene 1 T74105
30 131187 KPNA2 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) AA489087
31 111288 H. sapiens mRNA; cDNA DKFZp564C2063 (from clone DKFZp564C2063) AA416628
32 109170 C4A Complement component 4A AA664406
33 108203 TEGT Testis enhanced gene transcript (BAX inhibitor 1) AA629591
34 102639 EML2 Microtubule-associated protein like echinoderm EMAP R27580
35 131258 PSMA7 Proteasome (prosome, macropain) subunit, alpha type, 7 AI318565
36 123478 FLJ14712 Hypothetical protein FLJ14712 N79050
37 109415 FCGBP Fc fragment of IgG binding protein R52030
38 127815 PLAT Plasminogen activator, tissue R38933
39 115769 ESTs AA406313
40 106220 GIMAP5 Hypothetical protein FLJ11296 AA150443
41 128641 PTTG1 Pituitary tumour-transforming 1 AI362866
42 105439 TGOLN2 Trans-Golgi network protein (46-, 48-, 51-kD isoforms) T81338
43 101362 ERBB2 V-erb-b2 avian erythroblastic leukaemia viral oncogene homolog 2 (neuro/glioblastoma 
derived oncogene homolog)
AA446928
44 108387 IDH2 Isocitrate dehydrogenase 2 (NADP+), mitochondrial AA679907
45 100352 TGOLN2 Trans-Golgi network protein (46-, 48-, 51-kD isoforms) H82891
46 107941 PLAC8 Hypothetical protein AA150263
47 100104 SELL Selectin L (lymphocyte adhesion molecule 1) H00662
48 110983 DLEU1 Deleted in lymphocytic leukaemia, 1 AA425755
49 108438 GRB7 Growth factor receptor-bound protein 7 H53703
50 107752 PAG Phosphoprotein associated with GEMs N50114
51 128532 LTB Lymphotoxin beta (TNF superfamily, member 3) AI351740
52 124620 ASTN2 KIAA0634 protein AA404602
53 102357 CHN1 Chimerin (chimaerin) 1 AA598668
Table 5 (Continued)
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54 109454 AKR7A2 Aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) T62865
55 108678 CASP10 Caspase 10, apoptosis-related cysteine protease H80712
56 131111 CUGBP2 CUG triplet repeat, RNA-binding protein 2 AA047257
57 123475 C9orf87 Hypothetical protein FLJ10493 N53432
58 105013 EST H61003
59 100791 TDG Thymine-DNA glycosylase AA496947
60 100528 BCL2L2 BCL2-like 2 AA454588
61 116312 FLJ14299 Hypothetical protein FLJ14299 AA453170
62 100700 TRIB2 GS3955 protein AA458653
63 102004 PIK3R1 Phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) R54050
64 104569 MYO1B H. sapiens cDNA FLJ20153 fis, clone COL08656, highly similar to AJ001381 H. sapiens 
incomplete cDNA for a mutated allele
N95358
65 113907 SNRPB2 Small nuclear ribonucleoprotein polypeptide B" H00286
66 128683 WASL Wiskott-Aldrich syndrome-like AI261600
67 123768 DUSP22 Mitogen-activated protein kinase phosphatase x H42417
68 105099 RET Ret proto-oncogene (multiple endocrine neoplasia MEN2A, MEN2B and medullary thyroid 
carcinoma 1, Hirschsprung disease)
H24956
69 116859 STMN1 Leukaemia-associated phosphoprotein p18 (stathmin) AA873060
70 111660 FLJ13710 ESTs AA120866
71 100112 SAA1 Serum amyloid A1 H25546
72 100840 THOC1 Nuclear matrix protein p84 AA129297
73 129239 EST, Moderately similar to AF119917 63 PRO2831 [H. sapiens] W95750
74 115662 GIMAP4 Hypothetical protein FLJ11110 AA406363
75 109607 HTPAP ESTs T48412
76 108692 EMP2 Epithelial membrane protein 2 T88721
77 105133 JUNB Jun B proto-oncogene N94468
78 129959 LOC28335
2
EST AI023540
DCIS, ductal carcinoma in situ; EST, expressed sequence tag; NKI ID, Netherlands Cancer Institute (Amsterdam, The Netherlands) identification 
number.
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not have a sufficient number of cases to validate the gene
expression signatures that we identified.
We were able to show that well- (n = 6) and poorly (n = 14)
differentiated DCIS show different gene expression profiles
and can be distinguished by a classifier of 43 genes. Most of
the genes differentially expressed between well- and poorly
differentiated DCIS are involved in metabolism (for example,
BTD, ETFA, GMFG, and PLAT) and cell communication (for
example, ESR1, ACK1, CELSR2, and CCL19).
One of the top genes in the 43-gene classifier is BCL2. The
mRNA expression of this anti-apoptotic protein is upregulated
in the well-differentiated samples. In addition to its anti-apop-
Figure 4
Unsupervised hierarchical clustering of the in situ samples Unsupervised hierarchical clustering of the in situ samples. (a) Dendrogram of all 40 in situ samples. (b) Scaled-down representation of the entire 
cluster of (a) (5,788 genes). (c) Dendrogram of only the well- (n = 6) and poorly (n = 14) differentiated ductal carcinoma in situ (DCIS) cases. (d) 
Entire cluster of (c) (4,493 genes). Yellow indicates well-differentiated DCIS, brown indicates poorly differentiated DCIS, black indicates DCIS sam-
ples with an intermediately differentiated component, and gray indicates special cases. i, intermediately differentiated; IHC, immunohistochemistry; i-
p, intermediately-poorly differentiated; LCIS, lobular carcinoma in situ; p, poorly differentiated; w, well differentiated; w-i, well-intermediately differen-
tiated.Available online http://breast-cancer-research.com/content/8/5/R61
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totic function, BCL2 has a suggested role in neuro-endocrine
differentiation in colon carcinomas [31] and its downregula-
tion is associated with poor prognosis in breast cancer [32].
Twenty-eight of the 43 genes are upregulated and 15 genes
are downregulated in the well-differentiated samples (Figure
3a). Whereas a number of the 28 upregulated genes are
involved in DNA binding, no genes fulfilling this function are on
the list of the 15 downregulated genes. Conversely, genes
involved in phosphate metabolism (for example, GMFG,
ACK1, and ATP5B) can be found within the 15 downregu-
lated, but not in the 28 upregulated, genes.
It is known that HER2 is overexpressed in poorly differentiated
DCIS in approximately 42% of the cases [7], and it has been
suggested that HER2 overexpression is an early step in the
evolution of a distinct type of breast carcinoma. In our data set
of all in situ samples, we found a positive log2-ratio for HER
mRNA expression in six of 14 poorly differentiated DCIS cases
(43%) and in one case of intermediately-poorly differentiated
DCIS. In all the other in situ samples, the log2-ratios of HER2
are negative. These results are in agreement with the hypoth-
esis that HER2 overexpression is an early event in the devel-
opment of poorly differentiated in situ breast carcinomas.
Supervised classification of well-, well-intermediately, interme-
diately-poorly, and poorly differentiated DCIS samples (analy-
sis set 4) showed a separation of these samples in three
groups: a 'good' group, a 'poor' group, and an 'intermediate'
group containing mostly samples that were identified as inter-
mediately-poorly differentiated samples by pathologists. This
group also contains some samples pathologically classified as
well-intermediately differentiated, whereas most of these sam-
ples fall in the 'good' group. These results indicate that well-
and well-intermediately differentiated DCIS are more similar to
each other than poorly and intermediately-poorly differentiated
DCIS are. Following this idea, well- and well-intermediately dif-
ferentiated samples may be considered to be one group,
whereas poorly and intermediately-poorly differentiated sam-
ples seem to be two distinct groups of DCIS. If these results
can be validated in additional studies, this classification could
help to decrease controversial classification of DCIS due to
interobserver variability and to recognise well-differentiated
DCIS with more accuracy.
Within the gene lists describing the differences between well-
and poorly differentiated DCIS, a number of genes refer to pro-
teins for which antibodies are available. There is no single
gene discriminating between the different types of DCIS, but
it has to be investigated whether a combination of protein
stainings in a patient's tissue can assist in better classification
of DCIS. From the study presented here, potential candidates
for such an approach are Bcl-2, Ack1, CCL19, and CELSR2,
among others.
Thirty-five genes are able to describe the global differences in
gene expression between in situ and invasive breast tumour
samples. This classifier contains many genes involved in signal
transduction (for example, APC2, DAPK3, ADM, ARF1, and
IQGAP1) and cell growth and maintenance (TGFB2, PTMS,
PSAP, TUBB2, and MAP7).
The most likely model describing the progression from in situ
to invasive breast cancer lesions is the existence of distinct
pathways for the evolution of well- and poorly differentiated
DCIS. Following this idea, well-differentiated in situ lesions
develop into grade 1 IDC, whereas poorly differentiated sam-
ples develop into grade 3 IDC [5,6]. We therefore performed
supervised classification on the set of poorly differentiated
DCIS (n = 14) and grade 3 invasive breast cancer (n = 24).
Approximately 80 genes discriminate poorly differentiated in
situ from grade 3 invasive breast carcinomas. Thirteen of these
80 genes are upregulated and 67 genes are downregulated in
poorly differentiated DCIS samples. The genes in this classi-
fier are involved mostly in cell growth and protein metabolism.
Many of them have a function in protein binding (for example,
LCP1, TRAP1, ID4, TOB1, and CDH) and nucleic acid bind-
ing (for example, FBL,  PIAS4,  ELF3, EIF4G1,  NBS1, and
WHSC1L1).
A limited number of previous studies have addressed gene
expression profiles in DCIS, and most of these studies have
analysed a small number of samples. One study by Seth and
colleagues [20] compared one case of low- to intermediate-
grade DCIS with one case of high-grade DCIS with an inva-
sive component and identified genes upregulated or downreg-
ulated in the low- to intermediate-grade DCIS case. Adeyinka
and colleagues [19] studied six cases of DCIS with necrosis
and four samples of DCIS without necrosis and identified a
signature of 69 transcripts differentially expressed between
these two groups. Ma and colleagues [33] used laser capture
microdissection from paraffin-embedded material followed by
gene expression profiling to identify molecular signatures in
premalignant, preinvasive, and invasive stages of breast can-
cer. The results of their study suggested that tumour grade,
rather than tumour stage, is associated with distinct gene
expression patterns and that changes in gene expression
required for invasive growth are already present in the DCIS
stage [33]. In the study presented here, we compared the
gene expression profiles of poorly differentiated DCIS lesions
with those in grade 3 invasive breast tumours. In contrast to
Ma and colleagues, we did not compare paired samples from
the same patient but compared two groups of tumours. The
80-gene signature we identified is different from the signa-
tures describing the differences between different grades of
DCIS lesions. Schuetz and colleagues [34] identified gene
expression signatures of in situ and invasive breast cancer by
using 18 paired samples and combining laser capture micro-
dissection and gene expression profiling on oligonucleotideBreast Cancer Research    Vol 8 No 5    Hannemann et al.
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microarrays. They showed that 546 probes were differentially
expressed between DCIS and IDC. From the 18 genes they
validated by real-time polymerase chain reaction, four
(MMP11, PLAU, BGN, and FAP) are also present in our fil-
tered data sets of significantly regulated probe sets comparing
DCIS and invasive samples. They all show the same expres-
sion pattern as described by Schuetz and colleagues and are
expressed at higher levels in the groups of invasive tumours.
One of these genes (MMP11) is also part of the 35-gene and
80-gene classifiers. MMP11 and PLAU have already been
correlated to invasion and poor prognosis [35,36]. FAP
(seprase) is a membrane-bound protease that has been sug-
gested to reduce the dependence of breast cancer cells on
exogenous growth factors in vitro and thereby to facilitate
tumour growth and metastasis [37]. Allinen and colleagues
[38] identified comprehensive gene expression profiles of the
different cell types in normal breast, DCIS, and invasive breast
cancer tissue. These data show that dramatic gene expression
changes occur between normal breast tissue and breast car-
cinomas and that these changes are already present at the
DCIS stage. These results also suggest a role of the chemok-
ines CXCL12 and CXCL14 in breast tumourigenesis. Neither
chemokine is present on our array platform, but CXCR4, which
is the receptor for CXCL12, is. CXCR4 does not appear in the
set of significantly regulated genes, indicating that it does not
play a crucial role in our series of tumours, which reflects the
data of a mixed population of cells enriched for tumour cells,
whereas Allinen and colleagues performed gene expression
profiling on microdissected cell populations.
A recent study by Nagaraja and colleagues [39] describes
gene expression patterns corresponding to normal breast,
noninvasive breast cancer, and invasive breast cancer by
using several cell lines. They identified genes involved in cell-
cell and cell-matrix interactions which were altered in their
expression. A set of nine genes was sufficient to distinguish
between invasive and non-invasive cell lines [39]. From this set
of nine transcripts, six could be matched to our array platform.
For three of them (cadherin 11, annexin A1, and vimentin), we
observe the same expression pattern as published by Nagar-
aja and colleagues for the transition from in situ to invasive car-
cinoma. The other three transcripts (S100A8, claudin 3, and
cadherin 1) are upregulated in the invasive cancer cell line in
the data set of Nagaraja and colleagues, whereas we see a
downregulation in the invasive grade 3 tumours compared
with the group of poorly differentiated samples. This may be
due to the fact that Nagaraja and colleagues generated in vitro
data, which we compared with our human breast cancer data
set.
Porter and colleagues [40] identified a subset of genes that
are significantly regulated in DCIS or invasive carcinomas.
They identified 26 genes that were differentially expressed
between normal and DCIS samples or intermediate- and high-
grade DCIS, respectively. From these, only XBP1 is present in
one of our classifiers (78 genes). Porter and colleagues
describe this transcript as tumour-specific, meaning upregu-
lated in in situ and invasive tumours compared with their nor-
mal samples. We find that XBP1 is significantly more highly
expressed in well- and well-intermediately differentiated DCIS
samples than in poorly/intermediately-poorly differentiated
ones.
Wulfkuhle and colleagues [41] performed proteomic analyses
of six matched normal and DCIS samples of the human breast.
They identified proteins that are more highly expressed in indi-
vidual DCIS samples and that are involved in cytoskeletal reg-
ulation or vesicular trafficking or have chaperone activity. From
the 15 proteins from which the expression has been validated
by IHC, 12 are present as probes on our array platform. Three
of those (profilin, stathmin, and prohibitin) are differentially reg-
ulated between DCIS and invasive samples, and all three
show a higher expression in the invasive samples than in the
DCIS samples. This is in line with the paper of Wulfkuhle and
colleagues, which describes a higher expression of these pro-
teins in the DCIS samples than in normal tissue. This indicates
that changes in gene and protein expression observed in inva-
sive tumours are already present in the transition from normal
tissue to DCIS lesions.
Conclusion
We demonstrate here that gene expression profiling can dis-
tinguish between in situ breast cancer samples of well-versus
poorly differentiated type. There appear to be a group of poorly
differentiated samples, a group of well- and well-intermediately
differentiated samples, and a third group containing mainly
intermediately-poorly differentiated in situ cases. The quantita-
tive differences in gene expression between these groups are
mainly between twofold and fourfold. These differences are
difficult to detect by classical IHC, because this technique is
not very accurate in the quantification of small differences in
protein expression. So far, there are no single markers that dis-
tinguish between the different types of DCIS, but the possibil-
ity of identifying a manageable panel of markers to distinguish
the different types of DCIS lesions has to be further investi-
gated.
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